The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases

被引:39
作者
dos Reis Oliveira, Marcelo Braganca [1 ]
de Queiroz Mello, Fernanda Carvalho [2 ,3 ]
Machado Paschoal, Marcos Eduardo [3 ]
机构
[1] Univ Fed Rio de Janeiro, Trauma Orthopaed Serv, Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Fac Med, Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Thorac Dis Inst, Rio De Janeiro, Brazil
关键词
Lung cancer; Bone metastasis; SRE; Histology; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; PROGNOSTIC-FACTORS; SOLID TUMORS; DOUBLE-BLIND; PHASE-III; SURVIVAL; EPIDEMIOLOGY; PREDICTORS; PLACEBO;
D O I
10.1016/j.lungcan.2016.03.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Lung cancer is the leading cause of death due to cancer, and bone is one of the most frequent sites of metastasis. However, there is no published evidence regarding an association between lung cancer histology and skeletal complications. Therefore, we evaluated the influence of lung cancer histology on the frequency of bone metastases (BMs), skeletal-related events (SREs), and survival after BM. Material and methods: This retrospective study evaluated medical records from 413 patients who were diagnosed with lung cancer between 2003 and 2012. The prevalences of BMs and SREs were calculated, and their associations with the histological subtypes were evaluated using the chi-square test, odds ratios (OR), and 95% confidence intervals (CI). Overall survivals and associations with the histological subtypes were evaluated using the Kaplan-Meier method and the log-rank test. Results: The prevalences of BM, synchronous BM, and SREs were 28.2%, 70.4%, and 68.7%, respectively. Adenocarcinoma was the most common histological subtype (46.7%), and was significantly more frequent among patients with BM (58.3% vs. 42.1%; p = 0.003; OR: 1.92; 95% CI: 1.29-2.97). Squamous cell was significantly less frequent among patients with BM (13.0% vs. 29.8%; p = 0.0004; OR: 0.35; 95% CI: 0.19-0.64). The median survival time after the first BM diagnosis was 4 months, and there was no significant difference in the survival periods for the various histological subtypes. Conclusion: Adenocarcinoma and squamous cell were significantly associated with higher and lower risks of developing BM, respectively. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 50 条
  • [41] Prognostic score for life expectancy evaluation of lung cancer patients after bone metastasis
    Pruksakorn, Dumnoensun
    Phanphaisarn, Areerak
    Settakorn, Jongkolnee
    Arpornchayanon, Urarat
    Tantraworasin, Apichat
    Chaiyawat, Parunya
    Klangjorhor, Jeerawan
    Teeyakasem, Pimpisa
    [J]. JOURNAL OF BONE ONCOLOGY, 2018, 10 : 1 - 5
  • [42] Surgical treatment of bone metastases in patients with lung cancer
    Sandra Utzschneider
    Ewa Wicherek
    Patrick Weber
    Gerwin Schmidt
    Volkmar Jansson
    Hans Roland Dürr
    [J]. International Orthopaedics, 2011, 35 : 731 - 736
  • [43] Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
    Santini, D.
    Tampellini, M.
    Vincenzi, B.
    Ibrahim, T.
    Ortega, C.
    Virzi, V.
    Silvestris, N.
    Berardi, R.
    Masini, C.
    Calipari, N.
    Ottaviani, D.
    Catalano, V.
    Badalamenti, G.
    Giannicola, R.
    Fabbri, F.
    Venditti, O.
    Fratto, M. E.
    Mazzara, C.
    Latiano, T. P.
    Bertolini, F.
    Petrelli, F.
    Ottone, A.
    Caroti, C.
    Salvatore, L.
    Falcone, A.
    Giordani, P.
    Addeo, R.
    Aglietta, M.
    Cascinu, S.
    Barni, S.
    Maiello, E.
    Tonini, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (08) : 2072 - 2077
  • [44] Bone turnover markers and novel biomarkers in lung cancer bone metastases
    Lang, Jiangli
    Zhao, Qian
    He, Yuedong
    Yu, Xijie
    [J]. BIOMARKERS, 2018, 23 (06) : 518 - 526
  • [45] Bone-targeted agents in the treatment of lung cancer
    Silva, Shobha C.
    Wilson, Caroline
    Woll, Penella J.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (04) : 219 - 228
  • [46] Bone metastases in non-small cell lung cancer: a narrative review
    Knapp, Brendan J.
    Devarakonda, Siddhartha
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1696 - +
  • [47] A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
    Li, Wei
    Wu, Xinyu
    Yu, Heng
    Zhu, Zekai
    Li, Wenjie
    Huang, Xiang
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [48] Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
    Lipton, Allan
    Smith, Matthew R.
    Fizazi, Karim
    Stopeck, Alison T.
    Henry, David
    Brown, Janet E.
    Shore, Neal D.
    Saad, Fred
    Spencer, Andrew
    Zhu, Li
    Warner, Douglas J.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5713 - 5721
  • [49] A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe
    Body, Jean-Jacques
    von Moos, Roger
    Rider, Alex
    Hallworth, Pamela
    Bhowmik, Debajyoti
    Gatta, Francesca
    Hechmati, Guy
    Qian, Yi
    [J]. JOURNAL OF BONE ONCOLOGY, 2019, 14
  • [50] The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain
    Pockett, R. D.
    Castellano, D.
    McEwan, P.
    Oglesby, A.
    Barber, B. L.
    Chung, K.
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2010, 19 (06) : 755 - 760